According to the article published in the Journal of Clinical Oncology on February 5, 2015, BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. This rare occurrence has taken three decades to track, but confirms that in combination, these two characteristics increase the likelihood of the tumor developing from a low grade to a high grade tumor. For a brief synopsis, please click here. To read the full article, please click here.